D Koshanova
Research Subjects
D Koshanova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- A Phaizullaeva
Kazakhstan-Russian Medical University
1 shared publication - Aigul Karabaeva
Kazakhstan-Russian Medical University
1 shared publication - D Tazhdinov
“Mediterra” Center of Modern Medicine
1 shared publication - Gulnaz Saduakassova
Kazakhstan-Russian Medical University
1 shared publication - I Ibragimova
Kazakhstan-Russian Medical University
1 shared publication - N Yesenbayeva
Kazakhstan-Russian Medical University
1 shared publication
Latest Publications
- 31 December 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 85 (4) , 38
ECHOCARDIOGRAPHIC CHARACTERISTICS OF MYOCARDIAL STATUS IN PATIENTS WITH DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE AND ITS DYNAMICS IN DIALYSIS PATIENT UNDER SPIRONOLACTONE THERAPY
Background: The study aimed to evaluate myocardial status in patients with chronic kidney disease stages III–V and assess the effect of spironolactone in dialysis patients. Materials and Methods: A total of 46 patients with chronic kidney disease stages III–IV and 83 with stage V on maintenance hemodialysis were examined. Thirty-eight hemodialysis patients received spironolactone 25 mg/day for 6 months. Echocardiography was used to assess left ventricular dimensions, myocardial mass and relative wall thickness. Left ventricular hypertrophy was defined as left ventricular mass index ≥125 g/m² in men and ≥110 g/m² in women; relative wall thickness ≥0.45 was considered increased. Results: In spironolactone-treated patients (Group 1), left atrial diameter decreased from 4.58 ± 0.11 cm to 4.40 ± 0.11 cm; end-diastolic diameter from 4.15 ± 0.13 cm to 3.94 ± 0.17 cm; posterior wall thickness from 1.29 ± 0.03 cm to 1.23 ± 0.04 cm; Left ventricular myocardial mass from 238.46 ± 19.11 g to 206.18 ± 21.45 g; and Left ventricular mass index from 132.2 ± 10.81 g/m² to 113.32 ± 11.75 g/m². In untreated patients (Group 2), parameters showed minimal change: left atrial diameter 4.03 ± 0.11 cm to 3.90 ± 0.09 cm; Left ventricular myocardial mass 293.39 ± 17.13 g to 291.52 ± 15.43 g; Left ventricular mass index 173.57 ± 10.47 g/m² to 176.94 ± 10.06 g/m². Conclusion: In anuric hemodialysis patients, spironolactone 25 mg/day significantly reduced left ventricular posterior wall thickness, myocardial mass and volume, and left atrial size, indicating a cardioprotective effect.
- 31 December 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 85 (4) , 38
ECHOCARDIOGRAPHIC CHARACTERISTICS OF MYOCARDIAL STATUS IN PATIENTS WITH DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE AND ITS DYNAMICS IN DIALYSIS PATIENT UNDER SPIRONOLACTONE THERAPY
Background: The study aimed to evaluate myocardial status in patients with chronic kidney disease stages III–V and assess the effect of spironolactone in dialysis patients. Materials and Methods: A total of 46 patients with chronic kidney disease stages III–IV and 83 with stage V on maintenance hemodialysis were examined. Thirty-eight hemodialysis patients received spironolactone 25 mg/day for 6 months. Echocardiography was used to assess left ventricular dimensions, myocardial mass and relative wall thickness. Left ventricular hypertrophy was defined as left ventricular mass index ≥125 g/m² in men and ≥110 g/m² in women; relative wall thickness ≥0.45 was considered increased. Results: In spironolactone-treated patients (Group 1), left atrial diameter decreased from 4.58 ± 0.11 cm to 4.40 ± 0.11 cm; end-diastolic diameter from 4.15 ± 0.13 cm to 3.94 ± 0.17 cm; posterior wall thickness from 1.29 ± 0.03 cm to 1.23 ± 0.04 cm; Left ventricular myocardial mass from 238.46 ± 19.11 g to 206.18 ± 21.45 g; and Left ventricular mass index from 132.2 ± 10.81 g/m² to 113.32 ± 11.75 g/m². In untreated patients (Group 2), parameters showed minimal change: left atrial diameter 4.03 ± 0.11 cm to 3.90 ± 0.09 cm; Left ventricular myocardial mass 293.39 ± 17.13 g to 291.52 ± 15.43 g; Left ventricular mass index 173.57 ± 10.47 g/m² to 176.94 ± 10.06 g/m². Conclusion: In anuric hemodialysis patients, spironolactone 25 mg/day significantly reduced left ventricular posterior wall thickness, myocardial mass and volume, and left atrial size, indicating a cardioprotective effect.